The U.S. Food and Drug Administration approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer.
The U.S. Food and Drug Administration approved Jakafi (ruxolitinib), the first drug approved to specifically treat patients with the bone marrow disease myelofibrosis.
(Source: salutedomani.com)
Stress factors were the trigger for headaches or migraine attacks in two-thirds of the children examined at an outpatient clinic, Italian researchers reported at the 22nd Meeting of the European Neurological Society (ENS) in Prague.